First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Lifecore Biomedical, Inc.

    LFCR · 2 developments mapped · last assessed 2026-09-28

    Market Ontology has mapped 2 macro, policy, and market developments to Lifecore Biomedical, Inc. since 2026-09-28. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for LFCR yet, so no modelled value is shown. The LFCR valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run LFCR on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for LFCR. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      Webster Equity Partners to Acquire Lifecore Biomedical, Inc. ($664M)

      Direct acquisition premium and certainty of transaction close.

      · Moves equity value per share, liquidity premium

    • Main threat

      Webster Equity Partners to Acquire Lifecore Biomedical, Inc. ($664M)

      Delisting from public exchange upon completion of acquisition.

      · Moves public listing status

    What changed, by assumption

    Equity value per share
    • 2026-09-28Webster Equity Partners to Acquire Lifecore Biomedical, Inc. ($664M)
    Public listing status
    • 2026-09-28Webster Equity Partners to Acquire Lifecore Biomedical, Inc. ($664M)

    Assumption changes

    Full ledger →
    DateAssumptionDirectionWhyConf.
    2026-09-29Valuation multipleBullishTarget re-rates to bid premium until close.0.70
    2026-08-05MarginBullishCompany targeting Adjusted EBITDA margins exceeding 25% by the end of 2029 driven by cost reductions and productivity improvements.0.85
    2026-07-03Net debtBearishLiability-management transactions often reduce gross debt or push maturities out.0.70
    2026-07-03Interest expenseBearishTender/exchange extends maturity profile and typically lowers near-term interest expense.0.70

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-28Webster Equity Partners to Acquire Lifecore Biomedical, Inc. ($664M)Bullish1-5d0.90
    2026-09-28Webster Equity Partners to Acquire Lifecore Biomedical, Inc. ($664M)Bearish3-12m0.80